All In Biotech

Drug Trial Radar · NCT03443869

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Jul 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 601 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

601

Actual

Start

May 3, 2018

Primary completion

Apr 5, 2022

Study completion Apr 5, 2022

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients. The primary hypotheses are that LET is non-inferior to VGCV; and if non-inferiority is demonstrated, that LET is superior to VGCV, in preventing CMV disease through 52 weeks post-transplant.

Conditions

  • CMV Disease

Interventions

  • LetermovirDrug

    LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) once daily for 28 weeks

  • ValganciclovirDrug

    900 mg VGCV tablet orally, once daily for 28 weeks

  • Acyclovir (ACV)Drug

    400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks

  • Placebo to ACVDrug

    Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks

  • Placebo to LETDrug

    Placebo to LET tablet orally, once daily for 28 weeks

  • Placebo to VGCVDrug

    Placebo to VGCV tablet orally, once daily for 28 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adjudicated Cytomegalovirus (CMV) Disease Through 52 Weeks Post-transplantTime frame: Up to 52 weeks

Locations

94 sites in 16 countries. Site status is shown where the registry gives one.

  • UAB ( Site 0269)

    Birmingham, Alabama

  • UCLA Medical Center ( Site 0266)

    Los Angeles, California

  • UC Davis Medical Center ( Site 0271)

    Sacramento, California

  • University of California-San Francisco ( Site 0236)

    San Francisco, California

  • Stanford Health Care ( Site 0235)

    Stanford, California

  • The Emory Clinic ( Site 0247)

    Atlanta, Georgia

  • University of Chicago ( Site 0251)

    Chicago, Illinois

  • Indiana University ( Site 0261)

    Indianapolis, Indiana

  • Ochsner Clinic Foundation ( Site 0238)

    New Orleans, Louisiana

  • University of Maryland Medical Center ( Site 0234)

    Baltimore, Maryland

  • Johns Hopkins Hospital ( Site 0232)

    Baltimore, Maryland

  • Brigham & Women's Hospital ( Site 0244)

    Boston, Massachusetts

  • Henry Ford Hospital ( Site 0242)

    Detroit, Michigan

  • University of Nebraska Medical Center ( Site 0272)

    Omaha, Nebraska

  • Saint Barnabas Medical Center ( Site 0250)

    Livingston, New Jersey

  • Icahn School of Medicine at Mount Sinai ( Site 0256)

    New York, New York

  • Columbia University Medical Center ( Site 0255)

    New York, New York

  • New York Presbyterian Hospital - Weill Cornell Medical Center ( Site 0276)

    New York, New York

  • Duke University Medical Center ( Site 0243)

    Durham, North Carolina

  • Wake Forest University Baptist Medical Center ( Site 0260)

    Winston-Salem, North Carolina

  • The Ohio State University Wexner Medical Center ( Site 0264)

    Columbus, Ohio

  • University of Pennsylvania ( Site 0270)

    Philadelphia, Pennsylvania

  • University of Pittsburgh ( Site 0252)

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina ( Site 0257)

    Charleston, South Carolina

  • Vanderbilt University Medical Center ( Site 0275)

    Nashville, Tennessee

  • Virginia Commonwealth University ( Site 0245)

    Richmond, Virginia

  • University of Washington Medical Center ( Site 0246)

    Seattle, Washington

  • Instituto de Nefrologia Nephrology S.A. ( Site 0182)

    Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires ( Site 0188)

    CABA, Argentina

  • Instituto de Cardiología de Corrientes Juana F. Cabral ( Site 0181)

    Corrientes, Argentina

  • Clinica de nefrologia urologia y enfermedades cardiovasculares ( Site 0354)

    Santa Fe, Argentina

  • Hospital El Cruce Nestor Carlos Kirchner ( Site 0351)

    San Juan Bautista, Buenos Aires, Argentina

  • CEMIC ( Site 0352)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Royal Prince Alfred Hospital ( Site 0005)

    Camperdown, New South Wales, Australia

  • Westmead Hospital ( Site 0006)

    Westmead, New South Wales, Australia

  • Princess Alexandra Hospital ( Site 0004)

    Woolloongabba, Queensland, Australia

  • Royal Adelaide Hospital ( Site 0003)

    Adelaide, South Australia, Australia

  • Monash Health-Monash Medical Centre ( Site 0008)

    Clayton, Victoria, Australia

  • Royal Melbourne Hospital ( Site 0007)

    Parkville, Victoria, Australia

  • Allgemeines Krankenhaus Universitaetskliniken Wien ( Site 0032)

    Vienna, Austria

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.